Table of Contents
Jointly provided by:
This activity is supported by an educational grants from:
- AbbVie Inc., Amgen Inc.
- Bayer Healthcare
- Valeant Pharmaceuticals North America LLC.
Joseph F. Fowler, Jr, MD
Clinical Professor of Dermatology
University of Louisville
Christopher B. Zachary, MBBS, FRCP
Professor and Chair
Department of Dermatology
University of California, Irvine
The breadth and diversity of dermatology, the speed at which our understanding of skin pathophysiology has improved, and the introduction of new therapies combine to make this field interesting and challenging. The expanding scope of our specialty also creates a broad range of educational needs for practicing clinicians.
Skin Disease Education Foundation’s 39th Hawaii Dermatology Seminar offers updates from experts addressing a broad range of skin diseases, and covers advances in both medical and aesthetic dermatology. The articles in this educational supplement summarize the highlights of clinical sessions presented during the CME/CE conference by leading experts in the field of dermatology.
Tumor necrosis factor (TNF) inhibitors are the cornerstone of treatment for psoriasis, but choice of agent can be confusing. This supplement includes a comparison of the TNF inhibitors approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis. Psoriasis has been linked to an elevated risk of several comorbidities. Can choice of psoriasis therapy alleviate any of these conditions? Our faculty evaluates how risk or presence of comorbid conditions might inform the choice of psoriasis therapy, and whether control of psoriasis can alleviate any coexisting conditions.
Accumulating evidence suggests that rosacea, like psoriasis, is a disorder of the immune system – specifically, of innate rather than adaptive immunity. This CME/CE supplement summarizes those findings. It also reviews studies of new therapies for this condition, as well as new evidence validating the use of a commonly prescribed agent.
Moving from the face to the feet and from immune disorders to fungal infection, our faculty addresses the diagnosis and therapy for tinea pedis and toenail onychomycosis. The FDA last year approved two topical
therapies developed specifically for toenail onychomycosis, and in 2013 approved a treatment for interdigital tinea pedis. These highlights summarize the evidence for these therapies, and also cover other publications about diagnosis and management of these infections.
Acne is a common problem in dermatological practice. Our faculty reviews recent studies addressing topics such as antibiotic dosing, maintenance therapy, diet, and treatment of acne on the trunk of the body.
In the realm of aesthetic medicine, this educational supplement addresses techniques for reducing the number of sessions required for tattoo removal and newer lasers that may improve removal of certain types of tattoos.
The broad range of dermatology care and new therapies for skin conditions challenge the busy clinician to remain abreast of the latest information. We hope that you can apply these updates from our seminar to your clinical practice.
Individuals in a position to control the content of this educational activity are required to disclose: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients with the exemption of nonprofit or government organizations and non–health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Roger I. Ceilley, MD, Consultant: Ferndale Pharma Group, Inc, DUSA Pharmaceuticals, Inc., LEO Pharma Inc., Valeant Pharmaceuticals North America LLC, Xoft Inc.; Speakers Bureau: DUSA and LEO Pharma; Advisory Board: Ferndale, DUSA, Xoft Inc.
Kristina Callis Duffin, MD, MS, Grant/Research: AbbVie Inc., Amgen Inc., Bristol- Myers Squibb Company, Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Stiefel Laboratories, Inc., and XenoPort, Inc.; Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and XenoPort; Advisory Board: Eli Lilly and Janssen.
Joseph F. Fowler, Jr, MD, Grant/Research: AbbVie, Allergan, Inc., Amgen, Anacor Pharmaceuticals, Inc., Celgene Corporation, Chugai Pharma USA LLC, Eli Lilly, Galderma Laboratories, L.P., Genentech Inc, Janssen, Johnson & Johnson, Merck & Co., Inc., Novartis, Onset Dermatologics LLC, Pfizer, Regeneron Pharmaceuticals, Inc, SmartPractice Dermatology/Allergy, Taisho Pharmaceutical Co., Taro Pharmaceutical Industries Ltd, and Valeant; Consultant: Bayer Healthcare, Galderma, Johnson & Johnson, Medimetriks Pharmaceuticals Inc, Ranbaxy Laboratories Limited, and SmartPractice; Speakers Bureau: Galderma, SmartPractice, and Valeant.
Kenneth B. Gordon, MD, Grant/Research: AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer; Consultant: AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer.
Linda F. Stein Gold, MD, Consultant: Allergan, Anacor Pharmaceuticals, Celgene, Eli Lilly, Galderma, LEO Pharma, Novartis, and Valeant; Speakers Bureau: Celgene, Galderma, LEO Pharma, Novartis, Taro, and Valeant; Advisory Board: Allergan, Anacor Pharmaceuticals, Celgene, Eli Lilly, Galderma, LEO Pharma, Novartis, Promius Pharma, LLC, and Valeant; Medical Legal Advisor: Hoffmann- La Roche Inc.
Jerry K. L. Tan, MD, FRCPC, Grant/Research: Allergan, Bayer, Cipher Pharmaceuticals Inc, Dermira, Galderma, and Valeant; Consultant: Cipher Pharmaceuticals, Galderma, GlaxoSmithKline Pharmaceutical Company, Hoffmann-La Roche, Stiefel, and Valeant; Speakers Bureau: Cipher Pharmaceuticals, Galderma, Pierre-Fabre, and Valeant.
Christopher B. Zachary, MBBS, FRCP, Consultant: Cutera, Inc. and ZELTIQ Aesthetics, Inc.; Speakers Bureau: Cynosure, Inc. and Solta Medical, a division of Valeant; Advisory Board: ZELTIQ.